Lab Information
Peter Lakatos (MD)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Inflammatory bowel diseases (IBD) • gastroenterology • colitis • Crohn’s diseaseTeam Members
| Name | Position |
|---|
Latest Publications
- Hracs, L., Windsor, J. W., Gorospe, J., Cummings, M., Coward, S., Buie, M. J., Quan, J., Goddard, Q., Caplan, L., Markovinović, A., Williamson, T., Abbey, Y., Abdullah, M., Abreu, M. T., Ahuja, V., Raja Ali, R. A., Altuwaijri, M., Balderramo, D., Banerjee, R., Benchimol, E. I., Bernstein, C. N., Brunet-Mas, E., Burisch, J., Chong, V. H., Dotan, I., Dutta, U., El Ouali, S., Forbes, A., Forss, A., Gearry, R., Dao, V. H., Hartono, J. L., Hilmi, I., Hodges, P., Jones, G.-R., Juliao-Baños, F., Kaibullayeva, J., Kelly, P., Kobayashi, T., Kotze, P. G., Lakatos, P. L., Lees, C. W., Limsrivilai, J., Lo, B., Loftus, E. V., Ludvigsson, J. F., Mak, J. W. Y., Miao, Y., Ng, K. K., Okabayashi, S., Olén, O., Panaccione, R., Paudel, M. S., Quaresma, A. B., Rubin, D. T., Simadibrata, M., Sun, Y., Suzuki, H., Toro, M., Turner, D., Iade, B., Wei, S. C., Yamamoto-Furusho, J. K., Yang, S.-K., Ng, S. C., Kaplan, G. G. & Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group (2025). Global evolution of inflammatory bowel disease across epidemiologic stages. Nature.
- Angyal, D., Balogh, F., Bessissow, T., Wetwittayakhlang, P., Ilias, A., Gonczi, L. & Lakatos, P. L. (2025). The Role of Histology Alongside Clinical and Endoscopic Evaluation in the Management of IBD-A Narrative Review. Journal of clinical medicine, vol. 14.
- Candel, I., Wetwittayakhlang, P., Bessissow, T. & Lakatos, P. L. (2025). The Importance of Post-Inflammatory Polyps (PIPs) in Colorectal Cancer Surveillance in Inflammatory Bowel Diseases. Journal of clinical medicine, vol. 14.
- Balogh, F., Angyal, D., Ecseki, A. Á., Sebeszta, Z. V., Gönczi, L., Lontai, L., Miheller, P., Lakatos, P. & Iliás, Á. (2025). [Anemia classification, prevalence and predictive factors in inflammatory bowel disease]. Orvosi hetilap, vol. 166, p. 60-66.
- Farkas, B., Bessissow, T., Limdi, J. K., Sethi-Arora, K., Kagramanova, A., Knyazev, O., Bezzio, C., Armuzzi, A., Lukas, M., Michalopoulos, G., Chaskova, E., Savarino, E. V., Castiglione, F., Rispo, A., Schäfer, E., Saibeni, S., Filip, R., Attauabi, M., Fousekis, F. S., Bacsur, P., Resál, T., Bálint, A., Ivány, E., Szepes, Z., Bősze, Z., Fábián, A., Bor, R., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study. Journal of clinical medicine, vol. 13.
- Angyal, D., Gonczi, L., Balogh, F., Wetwittayakhlang, P., Golovics, P. A., Pandur, T., David, G., Erdelyi, Z., Szita, I., Ilias, A., Lakatos, L. & Lakatos, P. L. (2025). Inflammatory bowel diseases in the elderly population: epidemiology, long-term disease course, surgery rates, and biological use-data from the Veszprem county cohort between 1977 and 2020. Journal of Crohn's & colitis, vol. 19.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Wetwittayakhlang, P. & Lakatos, P. L. (2024). Advanced combination therapy: is it the best way to break the therapeutic ceiling?. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241272995.
- Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
See also
